Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 2Stomach Neoplasms 1Sarcoma, Synovial 1Platinum-Resistant Ovarian Carcinoma 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 9Nivolumab 5fludarabine 4Cyclophosphamide 4amatuximab 3Ipilimumab 3Fluorouracil 3Cisplatin 3tislelizumab 2spartalizumab 2budigalimab 2belinostat 2Hyperthermic Intraperitoneal Chemotherapy 2Cytoreduction Surgical Procedures 2Carboplatin 2venetoclax 1talazoparib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1atezolizumab 1aldesleukin 1Valacyclovir 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Immunotherapy, Adoptive × Gynecologic × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡